Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.0 million.

  • Mereo BioPharma Group's Net Income towards Common Stockholders rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of -$43.3 million for FY2024, which is 46.79% down from last year.
  • As of Q3 2025, Mereo BioPharma Group's Net Income towards Common Stockholders stood at -$7.0 million, which was up 51.94% from -$14.6 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Net Income towards Common Stockholders registered a high of -$1.8 million during Q2 2023, and its lowest value of -$15.0 million during Q3 2024.
  • Over the past 3 years, Mereo BioPharma Group's median Net Income towards Common Stockholders value was -$9.1 million (recorded in 2023), while the average stood at -$9.7 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Net Income towards Common Stockholders plummeted by 599.89% in 2024, and later soared by 53.18% in 2025.
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Net Income towards Common Stockholders stood at -$9.1 million in 2023, then grew by 22.65% to -$7.0 million in 2024, then surged by 53.18% to -$7.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$7.0 million in Q3 2025, compared to -$14.6 million in Q2 2025 and -$12.9 million in Q1 2025.